ReviewBMC public health2024
Cancer statistics in Yemen: incidence and mortality, in 2020.
Review in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Screen-detected cognitive impairment, psychological distress, and quality of life in cancer patients undergoing chemotherapy in Yemen.BMC psychology · 2026Article
- Evaluating Cancer Patients' Knowledge of Chemotherapy: Identifying Communication Gaps and Medication Errors in General Hospital of Thamar City.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Integrating Clinical and Molecular Insights: CTPS1 as a Key Biomarker of Tumor Progression and Prognosis in Colorectal Adenocarcinoma.Applied immunohistochemistry & molecular morphology : AIMM · 2026Article
- Polypharmacy and quality of life in Yemeni cancer patients undergoing chemotherapy: A cross-sectional study.PLOS global public health · 2026Article
- Public knowledge, attitudes, practices, and key influencing factors regarding cancer screening in Yemen.Conflict and health · 2025Article
- Seroprevalence and molecular detection of human t-cell lymphotropic virus type 1 among multi -transfused patients in Sana'a City, Yemen.BMC infectious diseases · 2025Article
- Oral Cancer Knowledge and Screening Practices Among Dental Professionals in Yemen: a Web-Based Survey.International dental journal · 2025Article
- Prevalence and determinants of depression and its association with social support among cancer patients: implications for enhancing oncology care.BMC psychology · 2025Article
- Nanoenzyme-based sensors for the detection of anti-tumor drugs.Mikrochimica acta · 2025Review
- Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.International journal of molecular sciences · 2024Review
- Nanomaterials: breaking the bottleneck of breast cancer drug resistance.Frontiers in immunology · 2024Review
- Cancer Genetics in the Arab World.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current cancer epidemiological profile in Yemen suffers from a lack of locally representative data and resources, posing a challenge in determining the real incidence, prevalence, survival and mortality rates, particularly data extracted from national hospitals. This study aims to provide a comprehensive overview of the cancer burden and trends in Yemen for 2020, including incidence and mortality rates.
methodsThe current study provides cancer statistics and their trends in Yemen, including incidence and mortality, in 2020 by using descriptive statistics. The data was obtained using the Global Cancer Observatory (GCO) 2020 online database.
resultsAccording to the (GCP) database in 2020, the crude incidence rate (CIR) of all cancers in Yemen was 55.2 per 100.000. The age-standardized rate (ASR) was 97.0 per 100.000, and the cumulative risk (0-74) was 22.0 per 100.000. The age-standardized rate (ASR) was 76.5 per 100.000, and the cumulative risk (0-74) was 19.6 per 100.000. Furthermore, the crude mortality rate (CIR) of all cancers was 40.6 per 100.000. Breast cancer was most prevalent in Yemen across all age groups and genders (31.1%), followed by colorectal cancer (7.7%) and leukemia (5.7%). Breast cancer also ranked as the primary cause of mortality at an estimated percentage of 13.5%, followed by colorectal cancer (8.8%) and stomach cancer (7.1%).
conclusionCancer has become a significant life-threatening illness in Yemen with an increase in the disease burden of breast cancer in women. Furthermore, leukemia in children and colorectal cancer in both sexes have experienced a more significant burden as well. Therefore, it is imperative for initiatives for cancer control and prevention to be prioritised at national and regional levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.